The Core was initiated in 2000 as a collaborative effort of the Cancer Center and the Prostate Cancer SPORE. In 2001 the Affymetrix and cDNA Microarray Core began the production of spotted cDNA microarrays, including a practice 'test'array, a 4.1K Human Cancer Array, a 5K Mouse Array, a 5K Human EST 'Gene Discovery'Array, and investigator-designed 'custom'microarrays. The Core began to offer Affymetrix technology on both a full- and partial-service basis in February 2002, with full-service including RNA analysis, probe labeling, fragmentation, hybridization, scanning and initial biostatistical analysis, and partial service including training laboratory personnel to perform the probe labeling and fragmentation steps. During the first fiscal year during which Affymetrix technology was made available (FY 2002), the Core recharged $18,125 in Affymetrix services to investigators. The service grew considerably over the next two years, and the Core recharged $300,403 in Affymetrix services during 2003 and $332,280 in 2004. The Core now provides spotted cDNA and Affymetrix technology to Cancer Center members representing most of the Center's research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-22
Application #
7917276
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
22
Fiscal Year
2009
Total Cost
$234,373
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865
Eberl, Markus; Mangelberger, Doris; Swanson, Jacob B et al. (2018) Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. Cancer Cell 33:229-243.e4
Lazarus, Jenny; Maj, Tomasz; Smith, J Joshua et al. (2018) Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 3:
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90

Showing the most recent 10 out of 1493 publications